Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial.

Background

Colorectal cancer (CRC) is the second most common cause of all cancer deaths in Europe and the Western world with a lifetime risk of approximately 5% [ 1 ]. Despite the implementation of early detection programs about 20–25% of all patients have already synchronous metastases at the time of diagnosis and approximately 25–50% will develop metastases in the course of disease mainly in liver and lung [ 2 , 3 ]. Liver metastases are the main cause of death and the only currently available curative therapy is the surgical R0 resection of metastases. Without any further treatment the median survival after metastases detection is poor with about 7.5 month [ 4 ].

For patients with unresectable disease several systemic treatment options are available. In recent years prognosis has been improved with median survival rates in clinical trials of up to 30 months [ 5 ]. The optimal treatment strategy is highly depending on the aim of the treatment, e.g. prolongation of survival, downsizing with secondary (potentially curative) resection, improving tumor-related symptoms, stopping tumor progression and/or maintaining quality of life, the side effect profile of the regimen, tumor -specific factors and comorbidities of the patient.

Combination chemotherapy regimens with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) provide higher response rates, longer progression-free survival (PFS) and better overall survival (OS) in first-line treatment compared to monotherapy regimens with 5-fluorouracil/leucovorin alone.

For patients with a good performance status and adequate organ function second-line chemotherapy should be offered. The chemotherapy regime in this situation is highly depending on the previous therapies, the therapy-free interval and pre-existing toxicities.

For patients who received an irinotecan-based regimen as first-line treatment the second-line treatment should consist of an oxaliplatin-containing combination (FOLFOX or capecitabine/oxaliplatin). For patients who received an oxaliplatin-based regimen as first-line treatment, the second-line treatment should be irinotecan-based (FOLFIRI or irinotecan alone) [ 6 , 7 ].

The combination of conventional chemotherapy with molecular targeted therapies such as the anti-vascular endothelial growth factor (anti-VEGF) agents bevacizumab, ramucirumab and aflibercept or the anti-epidermal growth factor receptor (anti-EGFR) agents cetuximab and panitumumab should be considered depending on the tumor biology. After second-line chemotherapy many patients are still in a good condition to receive third-line treatment depending on the organ function and pre-existing toxicities.

Despite the recent improvements in CRC therapy there is still the need of developing new treatment strategies for patients with metastatic chemorefractory disease. One important pathway which is constitutively active in 90% of CRC is the canonical Wnt/β-catenin pathway [ 8 ].

The S100 calcium binding protein A4 (S100A4) was identified as a Wnt/β-catenin target gene [ 9 ]. S100A4, originally named metastasin 1 (MTS1), is associated with many physiological processes (e.g. migration, invasion, wound healing, neovascularisation). S100A4 is able to induce metastases in different experimental in vitro and animal models [ 10 – 13 ]. S100A4 is overexpressed in many different types of cancer [ 14 , 15 ]. Its overexpression correlates with poor patients’ prognosis; high S100A4 levels are prognostic for metachronous metastases formation and correlate with reduced patient survival in several cancer types [ 16 – 22 ]. However, S100A4 itself is not tumorigenic as shown by Ambartsumian et al. because transgenic mice with an overexpression of S100A4 do not develop tumors per se [ 23 ].

In our own group we identified niclosamide as a transcriptional inhibitor of S100A4 expression by performing a high throughput screen for the human S100A4 promoter–driven reporter gene expression. Niclosamide is used since mid of the 1960s as an anti-helminthic drug which inhibits glucose uptake, oxidative phosphorylation and anaerobic metabolism [ 24 ]. Niclosamide is approved by the Food and Drug Administration (FDA) and the European medicines agency (EMA) for treatment of tapeworm infections.

Consequently, we demonstrated the efficacy of niclosamide in cell culture by inhibition of S100A4-induced cell migration and invasion. We identified niclosamide as anti-metastatic drug in colon cancer xenografted mice by restriction of liver metastases linked to shorter survival. In this experimental setting, niclosamide interfered in the Wnt signaling pathway by disrupting the complexation of β-catenin/TCF with the S100A4 promoter leading to reduced expression of S100A4 [ 13 ].

Other studies reported that niclosamide also interfered with the Wnt signaling pathways by inhibiting Wnt/Frizzled 1 signaling or by inducing the degradation of the Wnt co-receptor low density lipoprotein receptor-related protein 6 (LRP6) [ 25 , 26 ]. Osada et al. demonstrated a niclosamide-induced decrease in Dvl2 expression, leading to reduced downstream β-catenin signaling [ 27 ]. In hepatocellular cancer cells, niclosamide reduced cell proliferation, induced apoptosis, decreased TOP activity, and lowered β-catenin, Dvl2 and cyclin D1 levels [ 28 ]. Ono et al. reported niclosamide-induced reduction of proliferation of primary human leiomyoma cells by inhibiting Wnt/β-catenin pathway activation, such as inhibited TOP activity, down-regulated pathway target genes e.g. Axin2, and reduced nuclear β-catenin translocation [ 29 ]. Londoño-Joshi et al. demonstrated niclosamide-reduced levels of LRP6 and β-catenin for basal-like breast cancers [ 30 ]. For ovarian cancer, niclosamide treatment resulted in increased cytotoxicity, reduction of Wnt/β-catenin signaling by TOP assay, and decreased Wnt pathway proteins e.g. Axin2 and cyclin D1 [ 31 ]. King et al. demonstrated niclosamide-induced abrogation of Wnt7A/β-catenin signaling, inhibition of β-catenin transcriptional activity, cell viability, and decrease in cell migration [ 32 ]. Satoh et al. showed that niclosamide inhibited cell proliferation, induced caspase-dependent apoptosis and G1 cell cycle arrest, and decreased cell migration, reduced the level of mediators of epithelial-to-mesenchymal transition, and decreased β-catenin expression, [ 33 ]. Functionally, niclosamide is able to block further pathways besides Wnt/β-catenin signaling, known to be decisive for cancer initiation, progression and metastases [ 34 , 35 ]. For instance, it inhibits the mTORC1 activity by lysosomal dysfunction in different cancer types [ 36 – 38 ], blocks the STAT3 phosphorylation and its translocation to the nucleus in prostate cancer cells [ 39 ], and inhibits the NF-κB and Notch pathways [ 40 , 41 ]. Thus, niclosamide has been reported as an anti-cancer molecule in numerous cancer types like CRC [ 13 ], osteosarcoma [ 42 ], breast cancer [ 30 , 37 ], ovarian cancer [ 31 , 43 ], prostate cancer [ 44 ], non-small cell lung cancer (NSCLC) [ 45 , 46 ], glioblastoma [ 40 ], head and neck cancer [ 47 ], multiple myeloma, and leukemia [ 41 , 48 ].

Niclosamide has only little side effects and seems to be well tolerated even when applied over a long period [ 49 ]. The oral dose of niclosamide for adults in anti-helminthic treatments is 2 g on day one followed by 1 g daily for 6 consecutive days. The serum concentration of niclosamide after a single dose of 2 g leads to maximal serum concentrations of 0.25–6.0 μg/ml which corresponds to the concentration used on the above mentioned models [ 34 , 49 ].

As there is strong evidence from in vitro and in vivo experiments that niclosamide might be beneficial as anti-tumorigenic and anti-metastatic drug we designed the hereafter described clinical trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a CRC who progressed after therapy and for whom no other standard therapy is available.

Methods/Design

Study aims

This study evaluates the safety and efficacy of orally applied niclosamide in patients with metachronous or synchronous metastases of CRC origin, who progressed under previous therapy.

Study objectives

Primary objective is PFS after 4 months. PFS after 4 months will be evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.

Secondary objectives are OS, time to progression, disease control rate (remission + partial remission + stable disease), and safety.

Pharmacokinetic analysis will be done to investigate niclosamide plasma concentration and a potential correlation with efficacy.

Study design

The study is a phase II single center, one-arm open-label clinical trial for patients with metastatic CRC.

Study schedule

The trial has started on August 2015. The estimated accrual duration is 30 months. The estimated study completion date is 2018 (final data collection, date for primary outcome measure). Survival status will be collected for 2 years after registration.

Trial organization

The trial is organised by the Charité Comprehensive Cancer Center (CCCC) in collaboration with the Max-Delbrück-Center for Molecular Medicine (MDC), Berlin, Germany.

Statistics

The study is a one-arm open-label clinical trial with interim analyses for futility of patients with metastatic CRC.

A Simon two-stage design will be used to allow early termination due to futility. The null hypothesis is that the probability of being free of progression (having stable disease, partial or complete response) at 4 months is p 0 = 0.25 (H 0 : p < =p 0 = 0.25) estimated according to the recent literature [ 50 , 51 ]. This null hypothesis will be tested with the Binomial test one-sided against the alternative H 1 (estimated progression-free probability at 4 months of the experimental therapy) p1 = 0.5. Samples size for both stages were calculated according to the optimal design after Simon [ 52 ].

In the first stage 17 patients will be recruited. If less than 5 of the first 17 patients are progression-free at 4 months the trial will be terminated prematurely. Otherwise 20 additional patients will be enrolled (up to a total of 37 patients).

The null hypothesis will be rejected if at least 13 patients out of 37 will be free of progression at 4 months. This design (optimal design after Simon) yields a type I error rate of 0.046 and a power of 0.902.

Analyses of PFS and OS survival will performed with Kaplan-Meier-curves, hazard ration will be reported with 95% confidence intervals. For safety analysis the worst toxicities in each cycle will be reported according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. A descriptive analysis of adverse events (AEs) and serious adverse events (SAEs) will be provided.

Recruitment process

The trial is expected to take up to 30 months to complete recruitment. Participants will be recruited from the Charité Universitätsmedizin Berlin. Following verbal and written study information in form of the patient information sheet and extensive discussion with a clinical trial physician, patients will get at least 24 h time to consider participation.

Patients who meet all the inclusion criteria and none of the exclusion criteria listed in Table 1 will be invited to provide written informed consent. Table 1 Nikolo trial inclusion and exclusion criteria Inclusion criteria Disease related Patients with metachronous or synchronous metastases of a colorectal cancer progressing under standard therapy No proven brain metastases No curative option available No standard therapy available At least one metastasis has to be measurable according to RECIST V 1.1 in X-ray computed tomography or magnetic resonance imaging (not older than 2 weeks before inclusion into the trial) Demographic Age > 18 years Eastern Cooperative Oncology Group performance status ECOG 0–1 Laboratory Absolute neutrophil count ≥ 1.5 × 10 9 / L Platelet count ≥ 100 × 10 9 /L Leukocytes ≥ 1.0 × 10 9 /L Hemoglobin ≥ 9.0 g/dL or 5.59 mmol/l Bilirubin ≤ 2 x Upper Limit of Normal (ULN) if not due to Gilbert’s syndrome AST ≤ 2.5xULN in patients without liver metastases or ≤ 5.0xULN in patients with liver metastases ALT ≤ 2.5xULN in patients without liver metastases or < 5.0xULN in patients with liver metastases Adequate renal function (creatinine ≤ 1.5xULN) Ethical/Other Electrocardiography without clinical significant abnormalities Written informed consent before inclusion according to the ICH-GCP and national/local regulations Patients should use adequate birth control measures, during the study treatment period and for at least 3 months after the last study treatment Women of childbearing potential need to have a negative pregnancy test 72 h before the application of the first dose of niclosamide Patients who are breastfeeding must stop breastfeeding before the first dose of the study drug and not restart till 8 week after the last drug intake Exclusion criteria Concurrent conditions Pregnant or lactating females Other malignant disease (except colorectal cancer) within the last 5 years before inclusion in the trial except adequately treated basal cell carcinoma of the skin or squamous cell carcinoma of the skin, in situ carcinoma of the cervix. Patients with a malignant disease in history have to be free of disease for 5 years Clinical significant heart disease like e.g. uncontrolled blood pressure; heart failure NYHA grade > 2; cardiac infarction within the last 12 months Known uncontrolled concomitant disease despite treatment like e.g. chronic obstructive pulmonary disease Known alcohol or drug abuse Serious infection Any psychological, familial, sociological or geographical condition, potentially hampering compliance with the study protocol and follow-up schedule Ethical/Other Participation in another interventional study within the last 30 days Known hypersensitivity against a part of the study drug Life expectancy < 3 months Human immunodeficiency virus infection or active hepatitis B/C Patients that are committed to an institution by official or judicial order Persons that are depending on the sponsor, investigator or deputy

Study intervention and general considerations for dose modifications

Patients will start the treatment with the oral intake of 2 g niclosamide on day 1 and will continue with the medication once daily at the same time after a meal till disease progression or toxicity. Toxicities will be graded according to NCI CTCAE v4.03.

In case of an allergic reaction or vomiting ≥ grade II or diarrhoea or nausea or any other toxicity ≥ grade 3 the study medication will be paused until recovery and consequently reduced by one dose level (500 mg). If dose reductions to levels less than 1 g or discontinuation of the study treatment longer than 3 weeks are necessary, the study treatment will be terminated.

Assessments

Patients will be followed up closely for side effects. This includes physical examinations as well as blood tests. Additional intensive analyses of niclosamide levels in the blood will be conducted in the first patient cohort (patients 1–5) in the first week to examine the absorption of niclosamide from the intestine and systemic circulation. To assess efficacy imaging will be performed every 2 months to evaluate the disease status.

Translational research

Patients will be asked to consent for optional translational research including analysis of patients’ tumor tissue and additional blood analysis as described hereunder.

Analysis of S100A4 expression in patient primary tumors and/or metastases or recurrent tumors

If available, tumor tissue of the primary tumor and/or metastasis or recurrent tumor will be collected for patients who consent for optional translational research to do further analyses in specific subgroups (responder/non-responder). These tissues will be analyzed for S100A4 expression. These initial analyses characterizing the molecular starting point of the patient, depend on the availability of the amount of tissue procured for research purposes.

Analysis of potential niclosamide-induced effects on circulating S100A4 transcripts in patient plasma

The following initial analyses for characterization of the molecular starting point of the patient will be performed by using patients’ plasma for determination of the basal levels of circulating S100A4 transcripts.

Peripheral blood samples will be collected at baseline and at end of treatment (due to progression, toxicity or other reasons) for all patients. For patients who consented for the optional translational research additional blood samples will be collected during routine blood taking at week 1, week 4 and thereafter monthly until progression. Blood samples will be used to discover and validate the prognostic and predictive value of S100A4 as well as for response to niclosamide and to evaluate relationship between other clinical outcome parameters.

Plasma generation

Immediately after every blood taking, plasma will be generated. Blood initially collected in EDTA tubes will be processed in the lab for generation of plasma aliquots (400 μl volume) which will be stored frozen at − 80 °C. Analysis will be performed after completion of collection of all samples.

Additional analyses of further circulating transcripts such as beta-catenin might follow in patients who consented for the optional translational research.

Determination of niclosamide plasma concentration

Plasma samples (400 μl) are supplemented with acetonitrile (800 μl) containing naproxen (0.25 μg/ml). The mixture is vortexed for 30 s and centrifuged at 15000 g for 20 min at room temperature. An aliqoute of 800 μl of supernatant is withdrawn and evaporated to dryness (N2, 50 °C). The samples were reconstituted in 400 μl dilution solvent consisting of acetonitrile/methanol/water (5%/5%/90%, v /v/v) and subjected to HPLC.

HPLC (Shimadzu) will be performed with Trentec Select columns (RP C8 120 ODS3 5 μm; 125 × 3,0 mm with guard column; mobile phase A: acetonitrile/water/phosphoric acid (70/30/0.1, v /v/v); mobile phase B: acetonitrile/water/phosphoric acid (25/75/0.1, v/v/v); gradient: 0.01 min B 70%; 8 min B 70%; 8.1 min B 0%; 25 min B 0%; 25.1 min B 70%; flow rate: 0.5 ml/min). Time of analysis is 50 min, injector volume is 100 μl, detection l ABS [nm] is performed at 250 nm.

HPLC calibration curves of naproxen and niclosamide are linear in the range of 0.05 to 1 μg/ml concentration of each analyte of a dilution series in dilution solvent (= acetonitrile/methanol/water (5%/5%/90%, v/v/v). The parameters of a linear regression equation are as follows, naproxen: R2 = 0.9999, y = 216,017×; niclosamide: R2 = 0.9937, y = 230,993× confirming a good linearity for both analytes.

Determination of niclosamide in human plasma samples is done by HPLC (BioTez GmbH, Berlin).

Discussion

Several research groups and our own studies could show that niclosamide inhibits crucial pathways associated with proliferation, migration and invasion like the Wnt/β-catenin pathway, leading to anti-cancer activity of the drug. Niclosamide is initially EMA- and FDA-approved for anti-helminthic treatment and has a good safety profile, which creates a solid basis for repositioning this drug for alternate uses. Our preclinical studies supported the strong potential of niclosamide as anti-cancer drug, which interferes with tumor progression and metastases formation via S100A4 inhibition. However, its application in cancer patients has not been investigated in patients yet. Therefore, the use of niclosamide represents a novel approach of particularly metastases intervention via inhibition of a defined molecular target, such as S100A4.

To better explore the therapeutic potential of niclosamide there is the need to conduct a clinical trial to investigate the safety, efficacy and pharmacokinetics of orally applied niclosamide in cancer patients, and most importantly, to investigate if niclosamide treatment will result in prolongation of the PFS of the patients. The attractiveness of this study is based on the fact that the drug activity in patients will be correlated with the molecular analysis of the target molecule S100A4 in patient’s blood as the easiest accessible liquid biopsy for the timely monitoring. Furthermore, potential limiting factors, such as possible intra-individual difference in the drug absorption rate, will provide important additional information to what extend this will lead to variations of its anti-cancer efficacy.

As there is currently no predictive biomarker for response to niclosamide available we included an intense translational research program in our study to gain deeper insights in the mechanisms of niclosamide mediated anti-cancer activity. Thus, exploring the therapeutic potential of niclosamide in colon cancer patients in correlation to its target molecule S100A4 will enable us to evaluate this approach for broader uses in cancer therapy, where Wnt-signaling interference represents a rationale.

Abbreviations

Colorectal cancer

Common Terminology Criteria for Adverse Events

European medicines agency

Food and Drug Administration

5-fluorouracil/leucovorin/irinotecan

5-fluorouracil/leucovorin/oxaliplatin

International Conference on Harmonisation about Good Clinical Practice guidelines

Low density lipoprotein receptor-related protein 6

Metastasin 1

National Cancer Institute

Overall survival

Progression-free survival

Response Evaluation Criteria In Solid Tumors

S100 calcium binding protein A4

Upper Limit of Normal

Acknowledgements

The authors would like to thank the PreGoBio programm of the Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine and the the German Cancer Consortium (DKTK) for funding.

Funding

This work was supported by the PreGoBio program of the Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, and by the German Cancer Consortium (DKTK).

Availability of data and materials

Not applicable- this is a protocol paper outline of the study being conducted. All data supporting the development of the study are outlined in the manuscript.

Authors’ contributions

SB, US and WW wrote the manuscript. KN provided statistical counseling in clinical trial design. SB, US, UK and SD designed the study. All authors have read, critically reviewed and approved the final manuscript for publication.

Authors’ information

Susen Burock: Charité Comprehensive Cancer Center, Invalidenstraße 80, 10117 Berlin, Germany.

Severin Daum: Department of Medicine I, Gastroenterology, Rheumatology and Infectious Diseases, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12200 Berlin, Germany.

Ulrich Keilholz: Charité Comprehensive Cancer Center, Invalidenstraße 80, 10117 Berlin, Germany and German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

Konrad Neumann: Charité Comprehensive Cancer Center, Invalidenstraße 80, 10117 Berlin, Germany, Department for Biostatistics and Clinical Epidemiology, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany.

Wolfgang Walter: Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, 13125 Berlin, Germany.

Ulrike Stein: Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, 13125 Berlin, Germany and German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

Ethics approval and consent to participate

The final protocol was approved by the ethics committee of the Landesamt für Gesundheit und Soziales (LAGeSo), Berlin, Germany and the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) and is registered at EudraCT database (EudraCT 2014-005151-20) and at Clinicaltrials.gov ( NCT02519582 ).

This study complies with the Declaration of Helsinki in its recent version, the Medical Association’s professional code of conduct, the principles of the International Conference on Harmonisation about Good Clinical Practice guidelines (ICH-GCP) and the Federal Data Protection Act. The trial will also be carried out in keeping with local legal and regulatory requirements. The medical secrecy and the Federal Data Protection Act will be followed.

Written informed consent is obtained from each patient in oral and written form before inclusion in the trial and the nature, scope, and possible consequences of the trial have been explained by a physician. The investigator will not undertake any measures specifically required only for the clinical trial until valid consent has been obtained.

Competing interests

The authors declare that they have no competing interests, besides the following patent applications:

Stein U, Walther W, Sack U, Scudiero D, Schlag PM, Shoemaker RH. Niclosamide for treatment of cancer metastasis. US 14/112,521(12.11.2013), EP2012/057049 (18.4.2012).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Ferlay J Steliarova-Foucher E Lortet-Tieulent J Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 2013 49 1374 1403 10.1016/j.ejca.2012.12.027 23485231

2. Schmoll HJ Van CE Stein A ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Ann Oncol 2012 23 2479 2516 10.1093/annonc/mds236 23012255

3. Kanas GP Taylor A Primrose JN Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors Clin Epidemiol 2012 4 283 301 23152705 10.2147/CLEP.S34285 PMC3496330

4. Stangl R Altendorf-Hofmann A Charnley RM Factors influencing the natural history of colorectal liver metastases Lancet 1994 343 1405 1410 10.1016/S0140-6736(94)92529-1 7515134

5. Van CE Cervantes A Nordlinger B Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2014 25 Suppl 3 iii1 iii9 10.1093/annonc/mdu260 25190710

6. Rougier P Van CE Bajetta E Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Lancet 1998 352 1407 1412 10.1016/S0140-6736(98)03085-2 9807986

7. Seymour MT Maughan TS Ledermann JA Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Lancet 2007 370 143 152 10.1016/S0140-6736(07)61087-3 17630037

8. Giles RH van Es JH Clevers H Caught up in a Wnt storm: Wnt signaling in cancer Biochim Biophys Acta 2003 1653 1 24 12781368 10.1016/s0304-419x(03)00005-2

9. Stein U Arlt F Walther W The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer Gastroenterology 2006 131 1486 1500 10.1053/j.gastro.2006.08.041 17101323

10. Stein U Arlt F Smith J Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis Neoplasia 2011 13 131 144 10.1593/neo.101172 21403839 PMC3033592

11. Dahlmann M Okhrimenko A Marcinkowski P RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis Oncotarget 2014 5 3220 3233 10.18632/oncotarget.1908 24952599 PMC4102805

12. Sack U Walther W Scudiero D S100A4-induced cell motility and metastasis is restricted by the Wnt/beta-catenin pathway inhibitor calcimycin in colon cancer cells Mol Biol Cell 2011 22 3344 3354 10.1091/mbc.E10-09-0739 21795396 PMC3172260

13. Sack U Walther W Scudiero D Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer J Natl Cancer Inst 2011 103 1018 1036 10.1093/jnci/djr190 21685359

14. Schneider M Hansen JL Sheikh SP S100A4: a common mediator of epithelial-mesenchymal transition, fibrosis and regeneration in diseases? J Mol Med (Berl) 2008 86 507 522 10.1007/s00109-007-0301-3 18322670

15. Helfman DM Kim EJ Lukanidin E The metastasis associated protein S100A4: role in tumour progression and metastasis Br J Cancer 2005 92 1955 1958 10.1038/sj.bjc.6602613 15900299 PMC2361793

16. Boye K Nesland JM Sandstad B EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer Br J Cancer 2012 107 667 674 10.1038/bjc.2012.293 22782346 PMC3419949

17. Rud AK Lund-Iversen M Berge G Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer BMC Cancer 2012 12 333 10.1186/1471-2407-12-333 22853000 PMC3458900

18. Boye K Nesland JM Sandstad B Nuclear S100A4 is a novel prognostic marker in colorectal cancer Eur J Cancer 2010 46 2919 2925 10.1016/j.ejca.2010.07.013 20719498

19. Boye K Maelandsmo GM S100A4 and metastasis: a small actor playing many roles Am J Pathol 2010 176 528 535 10.2353/ajpath.2010.090526 20019188 PMC2808059

20. Natarajan J Hunter K Mutalik VS Overexpression of S100A4 as a biomarker of metastasis and recurrence in oral squamous cell carcinoma J Appl Oral Sci 2014 22 426 433 10.1590/1678-775720140133 25466476 PMC4245755

21. Huang H Zheng HY Liu ZL Prognostic significance of relaxin-2 and S100A4 expression in osteosarcoma Eur Rev Med Pharmacol Sci 2014 18 2828 2834 25339476

22. Stein U Burock S Herrmann P Diagnostic and prognostic value of metastasis inducer S100A4 transcripts in plasma of colon, rectal, and gastric cancer patients J Mol Diagn 2011 13 189 198 10.1016/j.jmoldx.2010.10.002 21354054 PMC3128604

23. Ambartsumian NS Grigorian MS Larsen IF Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene Oncogene 1996 13 1621 1630 8895507

24. Weinbach EC Garbus J Mechanism of action of reagents that uncouple oxidative phosphorylation Nature 1969 221 1016 1018 10.1038/2211016a0 4180173

25. Chen M Wang J Lu J The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling Biochemistry 2009 48 10267 10274 10.1021/bi9009677 19772353 PMC2801776

26. Chen W Chen M Barak LS Development of small molecules targeting the Wnt pathway for the treatment of colon cancer: a high-throughput screening approach Am J Physiol Gastrointest Liver Physiol 2010 299 G293 G300 10.1152/ajpgi.00005.2010 20508156 PMC2928541

27. Osada T Chen M Yang XY Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations Cancer Res 2011 71 4172 4182 10.1158/0008-5472.CAN-10-3978 21531761 PMC3117125

28. Tomizawa M Shinozaki F Motoyoshi Y Niclosamide suppresses hepatoma cell proliferation via the Wnt pathway Onco Targets Ther 2013 6 1685 1693 10.2147/OTT.S50065 24273411 PMC3836661

29. Ono M Yin P Navarro A Inhibition of canonical WNT signaling attenuates human leiomyoma cell growth Fertil Steril 2014 101 1441 1449 10.1016/j.fertnstert.2014.01.017 24534281 PMC4008647

30. Londono-Joshi AI Arend RC Aristizabal L Effect of niclosamide on basal-like breast cancers Mol Cancer Ther 2014 13 800 811 10.1158/1535-7163.MCT-13-0555 24552774 PMC3981919

31. Arend RC Londono-Joshi AI Samant RS Inhibition of Wnt/beta-catenin pathway by niclosamide: a therapeutic target for ovarian cancer Gynecol Oncol 2014 134 112 120 10.1016/j.ygyno.2014.04.005 24736023

32. King ML Lindberg ME Stodden GR WNT7A/beta-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer Oncogene 2015 34 3452 3462 10.1038/onc.2014.277 25174399 PMC4345161

33. Satoh K Zhang L Zhang Y Identification of niclosamide as a novel anticancer agent for adrenocortical carcinoma Clin Cancer Res 2016 22 3458 3466 10.1158/1078-0432.CCR-15-2256 26873959 PMC4947455

34. Li Y Li PK Roberts MJ Multi-targeted therapy of cancer by niclosamide: a new application for an old drug Cancer Lett 2014 349 8 14 10.1016/j.canlet.2014.04.003 24732808 PMC4166407

35. Pan JX Ding K Wang CY Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells Chin J Cancer 2012 31 178 184 10.5732/cjc.011.10290 22237038 PMC3777479

36. Li M Khambu B Zhang H Suppression of lysosome function induces autophagy via a feedback down-regulation of MTOR complex 1 (MTORC1) activity J Biol Chem 2013 288 35769 35780 10.1074/jbc.M113.511212 24174532 PMC3861628

37. Balgi AD Fonseca BD Donohue E Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling PLoS One 2009 4 e7124 10.1371/journal.pone.0007124 19771169 PMC2742736

38. Fonseca BD Diering GH Bidinosti MA Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling J Biol Chem 2012 287 17530 17545 10.1074/jbc.M112.359638 22474287 PMC3366846

39. Ren X Duan L He Q Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway ACS Med Chem Lett 2010 1 454 459 10.1021/ml100146z 24900231 PMC4007964

40. Wieland A Trageser D Gogolok S Anticancer effects of niclosamide in human glioblastoma Clin Cancer Res 2013 19 4124 4136 10.1158/1078-0432.CCR-12-2895 23908450

41. Jin Y Lu Z Ding K Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species Cancer Res 2010 70 2516 2527 10.1158/0008-5472.CAN-09-3950 20215516

42. Liao Z Nan G Yan Z The anthelmintic drug niclosamide inhibits the proliferative activity of human osteosarcoma cells by targeting multiple signal pathways Curr Cancer Drug Targets 2015 15 726 738 10.2174/1568009615666150629132157 26118906

43. Yo YT Lin YW Wang YC Growth inhibition of ovarian tumor-initiating cells by niclosamide Mol Cancer Ther 2012 11 1703 1712 10.1158/1535-7163.MCT-12-0002 22576131

44. Lu W Lin C Roberts MJ Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway PLoS One 2011 6 e29290 10.1371/journal.pone.0029290 22195040 PMC3241710

45. Li R Hu Z Sun SY Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer Mol Cancer Ther 2013 12 2200 2212 10.1158/1535-7163.MCT-13-0095 23894143 PMC3795834

46. Stewart RL Carpenter BL West DS S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide Oncotarget 2016 7 34630 34642 27127879 10.18632/oncotarget.8969 PMC5085181

47. Li R You S Hu Z Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer PLoS One 2013 8 e74670 10.1371/journal.pone.0074670 24019973 PMC3760825

48. Khanim FL Merrick BA Giles HV Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production Blood Cancer J 2011 1 e39 10.1038/bcj.2011.38 22829072 PMC3255256

49. Andrews P Thyssen J Lorke D The biology and toxicology of molluscicides, bayluscide Pharmacol Ther 1982 19 245 295 10.1016/0163-7258(82)90064-X 6763710

50. Grothey A Van CE Sobrero A Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 2013 381 303 312 10.1016/S0140-6736(12)61900-X 23177514

51. Van CE Tabernero J Lakomy R Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J Clin Oncol 2012 30 3499 3506 10.1200/JCO.2012.42.8201 22949147

52. Simon R Optimal two-stage designs for phase II clinical trials Control Clin Trials 1989 10 1 10 10.1016/0197-2456(89)90015-9 2702835